drugset
drugset / Trial / NCT03430232

First-In-Human PainCart Study for STR-324

NCT03430232 ↗

Phase 1 Completed 78 enrolled Stragen France
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an interventional, first-in-man study, double-blind, placebo-controlled, two-part, ascending doses study to investigate the safety, tolerability and efficacy of STR-324 infusions in healthy volunteers.

Timeline

Start
2018-02-20
Primary completion
2018-11-07
Completion
2018-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject STR-324 Unknown — Intravenous

Indications

No indication recorded.